Does the media refer more to EWTX or COLL?

In the previous week, Edgewise Therapeutics had 1 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 3 mentions for Edgewise Therapeutics and 2 mentions for Collegium Pharmaceutical. Edgewise Therapeutics' average media sentiment score of 1.54 beat Collegium Pharmaceutical's score of 0.96 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Collegium Pharmaceutical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to COLL or VKTX?

In the previous week, Viking Therapeutics had 8 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 10 mentions for Viking Therapeutics and 2 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 0.96 beat Viking Therapeutics' score of 0.76 indicating that Collegium Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Collegium Pharmaceutical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viking Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Collegium Pharmaceutical (COLL) Competitors

$36.20 +0.22 (+0.61%)

Closing price 06/30/2026 04:00 PM Eastern

Extended Trading

$36.21 +0.01 (+0.03%)

As of 06/30/2026 04:10 PM Eastern

Compare

COLL vs. KNSA, TNGX, EWTX, VKTX, and ACAD

Should you buy Collegium Pharmaceutical stock or one of its competitors? MarketBeat compares Collegium Pharmaceutical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Collegium Pharmaceutical include Kiniksa Pharmaceuticals International (KNSA), Tango Therapeutics (TNGX), Edgewise Therapeutics (EWTX), Viking Therapeutics (VKTX), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical products" industry.

How does Collegium Pharmaceutical compare to Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Collegium Pharmaceutical (NASDAQ:COLL) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

Kiniksa Pharmaceuticals International currently has a consensus target price of $62.71, indicating a potential downside of 1.93%. Collegium Pharmaceutical has a consensus target price of $57.50, indicating a potential upside of 58.84%. Given Collegium Pharmaceutical's higher probable upside, analysts clearly believe Collegium Pharmaceutical is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.83

Kiniksa Pharmaceuticals International has a beta of 0.12, meaning that its share price is 88% less volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

In the previous week, Kiniksa Pharmaceuticals International had 4 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 6 mentions for Kiniksa Pharmaceuticals International and 2 mentions for Collegium Pharmaceutical. Kiniksa Pharmaceuticals International's average media sentiment score of 1.13 beat Collegium Pharmaceutical's score of 0.96 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Collegium Pharmaceutical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Collegium Pharmaceutical has higher revenue and earnings than Kiniksa Pharmaceuticals International. Collegium Pharmaceutical is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	7.26	$59.01M	$0.90	71.06
Collegium Pharmaceutical	$780.57M	1.50	$62.87M	$2.04	17.75

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Collegium Pharmaceutical's net margin of 9.41%. Collegium Pharmaceutical's return on equity of 95.18% beat Kiniksa Pharmaceuticals International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%
Collegium Pharmaceutical	9.41%	95.18%	16.39%

54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are owned by insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Kiniksa Pharmaceuticals International beats Collegium Pharmaceutical on 9 of the 16 factors compared between the two stocks.

How does Collegium Pharmaceutical compare to Tango Therapeutics?

Collegium Pharmaceutical (NASDAQ:COLL) and Tango Therapeutics (NASDAQ:TNGX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

Collegium Pharmaceutical has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market.

79.0% of Tango Therapeutics shares are owned by institutional investors. 1.9% of Collegium Pharmaceutical shares are owned by company insiders. Comparatively, 6.5% of Tango Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Collegium Pharmaceutical has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57M	1.50	$62.87M	$2.04	17.75
Tango Therapeutics	$62.38M	72.49	-$101.59M	-$0.83	N/A

In the previous week, Collegium Pharmaceutical and Collegium Pharmaceutical both had 2 articles in the media. Tango Therapeutics' average media sentiment score of 1.43 beat Collegium Pharmaceutical's score of 0.96 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Collegium Pharmaceutical	Positive
Tango Therapeutics	Positive

Collegium Pharmaceutical currently has a consensus target price of $57.50, indicating a potential upside of 58.84%. Tango Therapeutics has a consensus target price of $41.50, indicating a potential upside of 32.76%. Given Collegium Pharmaceutical's stronger consensus rating and higher possible upside, equities analysts plainly believe Collegium Pharmaceutical is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.83
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73

Collegium Pharmaceutical has a net margin of 9.41% compared to Tango Therapeutics' net margin of -151.15%. Collegium Pharmaceutical's return on equity of 95.18% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	9.41%	95.18%	16.39%
Tango Therapeutics	-151.15%	-41.54%	-33.44%

Summary

Collegium Pharmaceutical beats Tango Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Collegium Pharmaceutical compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Collegium Pharmaceutical (NASDAQ:COLL) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

In the previous week, Edgewise Therapeutics had 1 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 3 mentions for Edgewise Therapeutics and 2 mentions for Collegium Pharmaceutical. Edgewise Therapeutics' average media sentiment score of 1.54 beat Collegium Pharmaceutical's score of 0.96 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Collegium Pharmaceutical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Collegium Pharmaceutical has a net margin of 9.41% compared to Edgewise Therapeutics' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 95.18% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-32.55%	-31.04%
Collegium Pharmaceutical	9.41%	95.18%	16.39%

Collegium Pharmaceutical has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A
Collegium Pharmaceutical	$780.57M	1.50	$62.87M	$2.04	17.75

Edgewise Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

Edgewise Therapeutics currently has a consensus target price of $47.30, suggesting a potential upside of 16.42%. Collegium Pharmaceutical has a consensus target price of $57.50, suggesting a potential upside of 58.84%. Given Collegium Pharmaceutical's stronger consensus rating and higher possible upside, analysts plainly believe Collegium Pharmaceutical is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Collegium Pharmaceutical beats Edgewise Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Collegium Pharmaceutical compare to Viking Therapeutics?

Collegium Pharmaceutical (NASDAQ:COLL) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Collegium Pharmaceutical currently has a consensus target price of $57.50, indicating a potential upside of 58.84%. Viking Therapeutics has a consensus target price of $93.60, indicating a potential upside of 139.94%. Given Viking Therapeutics' higher possible upside, analysts plainly believe Viking Therapeutics is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.83
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79

Collegium Pharmaceutical has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

In the previous week, Viking Therapeutics had 8 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 10 mentions for Viking Therapeutics and 2 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 0.96 beat Viking Therapeutics' score of 0.76 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Collegium Pharmaceutical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viking Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

76.0% of Viking Therapeutics shares are owned by institutional investors. 1.9% of Collegium Pharmaceutical shares are owned by insiders. Comparatively, 5.3% of Viking Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Collegium Pharmaceutical has a net margin of 9.41% compared to Viking Therapeutics' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 95.18% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	9.41%	95.18%	16.39%
Viking Therapeutics	N/A	-71.31%	-65.35%

Collegium Pharmaceutical has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57M	1.50	$62.87M	$2.04	17.75
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A

Summary

Collegium Pharmaceutical beats Viking Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Collegium Pharmaceutical compare to ACADIA Pharmaceuticals?

Collegium Pharmaceutical (NASDAQ:COLL) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

Collegium Pharmaceutical has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market.

ACADIA Pharmaceuticals has higher revenue and earnings than Collegium Pharmaceutical. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57M	1.50	$62.87M	$2.04	17.75
ACADIA Pharmaceuticals	$1.07B	4.04	$391M	$2.20	11.50

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 1.9% of Collegium Pharmaceutical shares are owned by company insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, ACADIA Pharmaceuticals had 15 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 17 mentions for ACADIA Pharmaceuticals and 2 mentions for Collegium Pharmaceutical. ACADIA Pharmaceuticals' average media sentiment score of 0.96 beat Collegium Pharmaceutical's score of 0.96 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Collegium Pharmaceutical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Collegium Pharmaceutical currently has a consensus price target of $57.50, suggesting a potential upside of 58.84%. ACADIA Pharmaceuticals has a consensus price target of $32.59, suggesting a potential upside of 28.81%. Given Collegium Pharmaceutical's stronger consensus rating and higher possible upside, analysts plainly believe Collegium Pharmaceutical is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.83
ACADIA Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65

ACADIA Pharmaceuticals has a net margin of 34.30% compared to Collegium Pharmaceutical's net margin of 9.41%. Collegium Pharmaceutical's return on equity of 95.18% beat ACADIA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	9.41%	95.18%	16.39%
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%

Summary

ACADIA Pharmaceuticals beats Collegium Pharmaceutical on 11 of the 17 factors compared between the two stocks.

Get Collegium Pharmaceutical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COLL vs. The Competition

Export

Metric	Collegium Pharmaceutical	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.17B	$3.08B	$7.07B	$12.45B
Dividend Yield	N/A	1.86%	2.66%	6.16%
P/E Ratio	17.75	19.38	27.51	24.87
Price / Sales	1.50	350.27	540.69	102.84
Price / Cash	2.36	57.53	48.53	58.59
Price / Book	3.79	4.28	11.01	6.54
Net Income	$62.87M	$64.45M	$3.57B	$336.70M
7 Day Performance	1.74%	3.18%	2.56%	3.31%
1 Month Performance	13.91%	3.80%	0.89%	1.68%
1 Year Performance	19.47%	34.43%	36.84%	31.96%

Collegium Pharmaceutical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COLL Collegium Pharmaceutical	2.6492 of 5 stars	$36.20 +0.6%	$57.50 +58.8%	+22.4%	$1.17B	$780.57M	17.75	210	Positive News
KNSA Kiniksa Pharmaceuticals International	3.0818 of 5 stars	$62.41 +5.4%	$62.71 +0.5%	+131.1%	$4.55B	$754.05M	69.34	220	News Coverage Positive News Analyst Forecast
TNGX Tango Therapeutics	3.0857 of 5 stars	$32.56 +3.5%	$41.50 +27.5%	+510.5%	$4.55B	$62.38M	N/A	90	Positive News Analyst Forecast
EWTX Edgewise Therapeutics	3.4568 of 5 stars	$40.92 -1.3%	$47.30 +15.6%	+209.9%	$4.46B	N/A	N/A	60
VKTX Viking Therapeutics	2.7964 of 5 stars	$39.54 +3.9%	$93.60 +136.7%	+47.2%	$4.42B	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COLL) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Collegium Pharmaceutical (COLL) Competitors

COLL vs. KNSA, TNGX, EWTX, VKTX, and ACAD

How does Collegium Pharmaceutical compare to Kiniksa Pharmaceuticals International?

Summary

How does Collegium Pharmaceutical compare to Tango Therapeutics?

Summary

How does Collegium Pharmaceutical compare to Edgewise Therapeutics?

Summary

How does Collegium Pharmaceutical compare to Viking Therapeutics?

Summary

How does Collegium Pharmaceutical compare to ACADIA Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COLL vs. The Competition

Collegium Pharmaceutical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Collegium Pharmaceutical (COLL) Competitors

COLL vs. KNSA, TNGX, EWTX, VKTX, and ACAD

How does Collegium Pharmaceutical compare to Kiniksa Pharmaceuticals International?

Do analysts prefer KNSA or COLL?

Which has more risk and volatility, KNSA or COLL?

Does the media prefer KNSA or COLL?

Which has preferable earnings & valuation, KNSA or COLL?

Is KNSA or COLL more profitable?

Do institutionals and insiders believe in KNSA or COLL?

Summary

How does Collegium Pharmaceutical compare to Tango Therapeutics?

Which has more volatility and risk, COLL or TNGX?

Do institutionals and insiders believe in COLL or TNGX?

Which has stronger earnings & valuation, COLL or TNGX?

Does the media prefer COLL or TNGX?

Do analysts recommend COLL or TNGX?

Is COLL or TNGX more profitable?

Summary

How does Collegium Pharmaceutical compare to Edgewise Therapeutics?

Does the media refer more to EWTX or COLL?

Is EWTX or COLL more profitable?

Which has stronger earnings and valuation, EWTX or COLL?

Which has more volatility & risk, EWTX or COLL?

Do analysts rate EWTX or COLL?

Summary

How does Collegium Pharmaceutical compare to Viking Therapeutics?

Do analysts prefer COLL or VKTX?

Which has more volatility and risk, COLL or VKTX?

Does the media refer more to COLL or VKTX?

Do insiders and institutionals have more ownership in COLL or VKTX?

Is COLL or VKTX more profitable?

Which has stronger valuation and earnings, COLL or VKTX?

Summary

How does Collegium Pharmaceutical compare to ACADIA Pharmaceuticals?

Which has more volatility and risk, COLL or ACAD?

Which has higher valuation and earnings, COLL or ACAD?

Do insiders and institutionals hold more shares of COLL or ACAD?

Does the media favor COLL or ACAD?

Do analysts prefer COLL or ACAD?

Is COLL or ACAD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COLL vs. The Competition

Collegium Pharmaceutical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools